10-K/A ·Filed Apr 30, 2026
Amended annual report (potential restatement)
Actionable Insight • Neutral
This filing contains no new financial data or strategic developments. Monitor future filings for any operational updates or guidance changes.
Final — all horizons settled through T+60d
VNRX ▼ -64.97% at T+60d
NEUTRAL call -64.97% · α vs SPY -68.04% · entry $2.43 → $0.8513
T+1d
-1.65%
call -1.65% · α -1.30%
$2.39
settled 6mo ago
T+5d
-7.41%
call -7.41% · α -9.75%
$2.25
settled 6mo ago
T+20d
+9.05%
call +9.05% · α +3.79%
$2.65
settled 5mo ago
T+60d
-64.97%
call -64.97% · α -68.04%
$0.8513
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
VolitionRx filed Amendment No. 1 to its 2025 Form 10-K solely to include Part III information (directors, executive compensation, beneficial ownership, related transactions, and auditor fees) that was previously omitted. This is a routine administrative filing with no restatements or changes to financial statements.
Key Facts
- Amendment filed to provide Part III info (Items 10-14) omitted from the original 10-K
- No restatements, auditor changes, or material financial adjustments
- Includes details on director compensation, insider holdings, and related party transactions
- Company effected a 1-for-20 reverse stock split in April 2026
Financial Impact
No financial impact; purely administrative amendment
Risk Factors
- No material risks identified from this filing
Market Snapshot
Exchange
NYSE
Sector
In Vitro & In Vivo Diagnostic Substances
Analyst Consensus
82% bullish (11 analysts)
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-K/A Filing (Primary) | 0001477932-26-002685 |
| Document: vnrx_313.htm | 0001477932-26-002685 |
| Document: vnrx_314.htm | 0001477932-26-002685 |
| Document: 0001477932-26-002685-index-headers.html | 0001477932-26-002685 |
| Document: 0001477932-26-002685-index.html | 0001477932-26-002685 |
| Document: 0001477932-26-002685.txt | 0001477932-26-002685 |
19 reports for VNRX
100% Hit rate @ T+60 Went positive at some point 12 of 13 best @ T+60▲ +83.65%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 8-K | $0.2529 | awaiting T+60 | — | $0.1800 (+28.83%) |
Sep 16, 2026 5w ago | SC 13D/A | $0.2849 | awaiting T+60 | — | $0.1800 (−36.82%) |
Sep 15, 2026 5w ago | 8-K | $0.2749 | awaiting T+60 | — | $0.1800 (+34.52%) |
Sep 11, 2026 6w ago | EFFECT | $0.3102 | awaiting T+60 | — | $0.1800 (+41.97%) |
Sep 8, 2026 6w ago | S-3/A | $0.3400 | awaiting T+60 | — | $0.1800 (+47.06%) |
Sep 1, 2026 7w ago | 8-K | $0.3800 | awaiting T+60 | — | $0.1800 (+52.63%) |
Aug 24, 2026 9w ago | 8-K | $0.3846 | awaiting T+60 | — | $0.1800 (+53.20%) |
Aug 7, 2026 11w ago | 8-K | $0.7700 | awaiting T+60 | — | $0.1800 (+76.62%) |
Jul 20, 2026 14w ago | EFFECT | $1.13 $0.1847 | ▲ +83.65% | ▲ +88.50% | $0.1800 (+84.07%) |
Jun 18, 2026 18w ago | 8-K | $1.34 | awaiting T+60 | — | $0.1800 (+86.57%) |
Showing 10 of 19
US Market Status
Market Closed — Opens Wed (11h 52m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers